课题基金 / 基金详情

Defining the mechanism of toxicity from loss of immune checkpoints

Defining the mechanism of toxicity from loss of immune checkpoints
定义免疫检查点丧失引起的毒性机制
批准号:
MC_UU_00025/12
负责人:
James Thaventhiran
金额:
$249.62万
依托单位:
依托单位国家:
英国
项目类别:
Intramural
财政年份:
2020
资助国家:
英国
项目状态:
已结题
起止时间:
2020 至 --

项目摘要

项目成果

James Thaventhiran的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Cancer treatment has improved with immune checkpoint blockade, boosting the immune system’s ability to target tumours. New therapies using modified mRNA vaccines promise even better outcomes. However, these treatments can sometimes cause serious side effects by activating immune cells that mistakenly attack the body’s own tissues. Our research aims to understand why these side effects happen and find ways to make these therapies safer.Our Approach:1. Studying Patients:o We examine patients treated with immune checkpoint blockade or modified mRNA vaccines to see how their immune systems are affected.o By comparing them to people with rare genetic diseases affecting the immune system, we confirm that the side effects are directly caused by the treatments.2. Using Animal Models:o We use mice to model immune system problems, helping us study their causes.o These models allow us to test different treatments and immune adjustments to prevent or reduce side effects.Our Goal:Combining patient studies with animal research, we aim to improve the safety of cancer treatments. Understanding these side effects will help us develop therapies that are both effective and safe, leading to better outcomes for cancer patients.
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1101/2022.05.24.493238
发表时间: 2022-11
期刊: bioRxiv
影响因子: --
作者: [V. Graziano;Andreas Dannhorn;Heather Hulme;K. Williamson;Hannah Buckley;Saadia A. Karim;Sheng Y. Lee;B. P. Kaistha;Sabita Islam;James E. D. Thaventhiran;F. Richards;R. Goodwin;R. Brais;J. Morton;S. Dovedi;A. Schuller;J. Eyles;D. Jodrell]
通讯作者: V. Graziano;Andreas Dannhorn;Heather Hulme;K. Williamson;Hannah Buckley;Saadia A. Karim;Sheng Y. Lee;B. P. Kaistha;Sabita Islam;James E. D. Thaventhiran;F. Richards;R. Goodwin;R. Brais;J. Morton;S. Dovedi;A. Schuller;J. Eyles;D. Jodrell
Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report
在缺乏体液免疫的情况下使用瑞德西韦治疗 COVID-19:病例报告
DOI: 10.17863/cam.62498
发表时间: 2020
期刊:
影响因子: --
作者: [Buckland M]
通讯作者: Buckland M
Publisher Correction: Whole-genome sequencing of a sporadic primary immunodeficiency cohort.
出版商更正:散发性原发性免疫缺陷队列的全基因组测序。
DOI: 10.1038/s41586-020-2556-6
发表时间: 2020
期刊: Nature
影响因子: 64.8
作者: [Thaventhiran JED]
通讯作者: Thaventhiran JED
DOI: 10.1073/pnas.2013644117
发表时间: 2020-11-17
期刊: Proceedings of the National Academy of Sciences of the United States of America
影响因子: 11.1
作者: [Biasci D, Smoragiewicz M, Connell CM, Wang Z, Gao Y, Thaventhiran JED, Basu B, Magiera L, Johnson TI, Bax L, Gopinathan A, Isherwood C, Gallagher FA, Pawula M, Hudecova I, Gale D, Rosenfeld N, Barmpounakis P, Popa EC, Brais R, Godfrey E, Mir F, Richards FM, Fearon DT, Janowitz T, Jodrell DI]
通讯作者: Jodrell DI
7
    SARS COV2 vaccine ResPonse In Obesity - SCORPIO study
    • 批准号:
      MR/W020564/1
    • 项目类别:
      Research Grant
    • 资助金额:
      $95.86万
    • 财政年份:
      2021
    • 负责人:
      James Thaventhiran
    • 依托单位:
    Definition of the differential proliferative tissue damaging and transcriptional responses in endogenously TCR- triggered lymphocytes versus foreign antigen stimulated lymphocytes induced by checkpoint blockade
    • 批准号:
      MC_EX_MR/S300011/1
    • 项目类别:
      Fellowship
    • 资助金额:
      $63.71万
    • 财政年份:
      2018
    • 负责人:
      James Thaventhiran
    • 依托单位:
    Defining the role of STAT1 acetylation in adaptive immunity.
    • 批准号:
      MR/L006197/1
    • 项目类别:
      Fellowship
    • 资助金额:
      $144.5万
    • 财政年份:
      2014
    • 负责人:
      James Thaventhiran
    • 依托单位:
    国内基金
    海外基金
    配子生成素GGN不同位点突变损伤分子伴侣BIP及HSP90B1功能导致精子形成障碍的发病机理
    • 批准号:
      82371616
    • 项目类别:
      面上项目
    • 资助金额:
      49.00万元
    • 批准年份:
      2023
    • 负责人:
      姚晨成
    • 依托单位:
    糖尿病ED中成纤维细胞衰老调控内皮细胞线粒体稳态失衡的机制研究
    • 批准号:
      82371634
    • 项目类别:
      面上项目
    • 资助金额:
      49.00万元
    • 批准年份:
      2023
    • 负责人:
      赵福军
    • 依托单位:
    生物钟核受体Rev-erbα在缺血性卒中神经元能量代谢中的改善作用及机制研究
    • 批准号:
      82371332
    • 项目类别:
      面上项目
    • 资助金额:
      49.00万元
    • 批准年份:
      2023
    • 负责人:
      胡琴
    • 依托单位:
    超声驱动压电效应激活门控离子通道促眼眶膜内成骨的作用及机制研究
    • 批准号:
      82371103
    • 项目类别:
      面上项目
    • 资助金额:
      49.00万元
    • 批准年份:
      2023
    • 负责人:
      阮静
    • 依托单位: